Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses CRBU in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CRBU in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Rachel Haurwitz | $667,534 | $312,072 | $192,818 | $654,541 | $0 | $0 | $14,000 | $1,840,965 |
| President and Chief Executive Officer | ||||||||
| Sriram Ryali | 483,163 | 164,900 | 0 | 367,350 | 0 | 0 | 14,000 | 1,029,413 |
| Chief Financial Officer | ||||||||
| Barbara McClung | 502,030 | 170,690 | 52,875 | 179,979 | 0 | 0 | 14,000 | 919,574 |
| Chief Legal Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Rachel Haurwitz | $1,840,965 | $4,213,245 | $3,116,547 | −2,372,280 |
| Sriram Ryali | 1,029,413 | — | — | — |
| Barbara McClung | 919,574 | 1,612,819 | 1,217,807 | −693,245 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Rachel Haurwitz | RSU | 2025-02-20 | — | — | 136,750 | — | $192,818 |
| Barbara McClung | PSU | 2025-07-21 | — | 113,333 | — | — | — |
| Barbara McClung | OPTION | 2025-02-20 | — | — | 170,000 | — | 206,898 |
| Rachel Haurwitz | PSU | 2025-07-21 | — | 412,167 | — | — | — |
| Rachel Haurwitz | OPTION | 2025-02-20 | — | — | 618,250 | — | 752,440 |
| Sriram Ryali | OPTION | 2025-01-10 | — | — | 300,000 | — | 427,604 |
| Sriram Ryali | PSU | 2025-07-21 | — | 113,333 | — | — | — |
| Barbara McClung | RSU | 2025-02-20 | — | — | 37,500 | — | 52,875 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Rachel Haurwitz | $192,818 | $0 | $752,440 | 0.0% |
| Barbara McClung | 52,875 | 0 | 206,898 | 0.0% |
| Sriram Ryali | 0 | 0 | 427,604 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Barbara McClung | RSU | 37,500 | — | $59,625 |
| Barbara McClung | RSU | 24,750 | — | 39,353 |
| Rachel Haurwitz | Option | 148,896 | 6.12 | — |
| Rachel Haurwitz | RSU | 89,025 | — | 141,550 |
| Rachel Haurwitz | Option | 618,250 | 1.41 | — |
| Barbara McClung | Option | 38,209 | 6.12 | — |
| Sriram Ryali | Option | 300,000 | 1.64 | — |
| Rachel Haurwitz | Option | 412,167 | 2.07 | — |
| Sriram Ryali | Option | 113,333 | 2.07 | — |
| Barbara McClung | Option | 82,875 | 6.81 | — |
| Barbara McClung | Option | 113,333 | 2.07 | — |
| Rachel Haurwitz | RSU | 136,750 | — | 217,433 |
| Barbara McClung | Option | 170,000 | 1.41 | — |
| Rachel Haurwitz | Option | 296,265 | 6.81 | — |
Caribou Biosciences compensates its executive officers through a combination of base salary, annual cash bonuses, and equity-based awards, with the goal of attracting, retaining, and motivating qualified executives. Compensation is designed to reward achievement of defined company strategic goals and to align executive officer interests with those of stockholders.
| CEO STI target (% of salary) | 55% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Andrew GuggenhimeIndependent · Board Chair · Audit (Chair) · Compensation | $97,578 | $0 | $40,929 | $0 | $0 | $138,507 |
| Ran ZhengIndependent · Nominating/Governance · Science and Technology | 59,171 | 0 | 40,929 | 0 | 0 | 100,100 |
| Nancy WhitingIndependent · Compensation · Science and Technology (Chair) | 57,312 | 0 | 40,929 | 0 | 0 | 98,241 |
| Natalie SacksIndependent · Nominating/Governance (Chair) · Science and Technology | 55,000 | 0 | 40,929 | 0 | 0 | 95,929 |
| Dara Richardson-HeronIndependent · Nominating/Governance | 50,408 | 0 | 40,929 | 0 | 0 | 91,337 |
| Scott BraunsteinIndependent · Audit · Compensation (Chair) | 49,589 | 0 | 40,929 | 0 | 0 | 90,518 |
| David JohnsonIndependent · Audit | 49,090 | 0 | 40,929 | 0 | 0 | 90,019 |
| Rachel HaurwitzEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $40,929 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $418,148 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $418,148 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Caribou Biosciences, Inc. | 2025 | Rachel Haurwitz | $667,534 | $192,818 | $654,541 | $0 | $1,840,965 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Rachel Haurwitz | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Summary Compensation Table (2025 and 2024)”. As printed: 1,840,965. Filing ↗machine: r2 · c39 · span 189876–189885 |
| 2 | Section 01, Sriram Ryali | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Summary Compensation Table (2025 and 2024)”. As printed: 1,029,413. Filing ↗machine: r4 · c39 · span 195843–195852 |
| 3 | Section 01, Barbara McClung | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Summary Compensation Table (2025 and 2024)”. As printed: 919,574. Filing ↗machine: r6 · c39 · span 199904–199911 |
| 4 | Section 03, Rachel Haurwitz RSU | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 210554–210561 |
| 5 | Section 03, Barbara McClung PSU | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 209284–209291 |
| 6 | Section 03, Barbara McClung OPTION | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 209965–209972 |
| 7 | Section 03, Rachel Haurwitz PSU | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 209275–209282 |
| 8 | Section 03, Rachel Haurwitz OPTION | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 209952–209959 |
| 9 | Section 03, Sriram Ryali OPTION | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 211240–211247 |
| 10 | Section 03, Sriram Ryali PSU | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “EXECUTIVE AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: span 209284–209291 |
| 11 | Section 03, Barbara McClung RSU | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Summary Compensation Table” · grants of plan-based awards table. Filing ↗machine: t9 · r6 · c9 · span 198676–198682 |
| 12 | Section 07, pay ratio | 10-K | 2026-03-05 | 0001619856-26-000008 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 13 | Section 08, Andrew Guggenhime | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Director Compensation”. As printed: 138,507. Filing ↗machine: t11 · r4 · c10 · span 346690–346697 |
| 14 | Section 08, Ran Zheng | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Director Compensation”. As printed: 100,100. Filing ↗machine: t11 · r9 · c10 · span 356817–356824 |
| 15 | Section 08, Nancy Whiting | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Director Compensation”. As printed: 98,241. Filing ↗machine: t11 · r8 · c10 · span 354800–354806 |
| 16 | Section 08, Natalie Sacks | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Director Compensation”. As printed: 95,929. Filing ↗machine: t11 · r7 · c10 · span 352775–352781 |
| 17 | Section 08, Dara Richardson-Heron | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Director Compensation”. As printed: 91,337. Filing ↗machine: t11 · r6 · c10 · span 350754–350760 |
| 18 | Section 08, Scott Braunstein | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Director Compensation”. As printed: 90,518. Filing ↗machine: t11 · r3 · c10 · span 344663–344669 |
| 19 | Section 08, David Johnson | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Director Compensation”. As printed: 90,019. Filing ↗machine: t11 · r5 · c10 · span 348725–348731 |
| 20 | Section 08, Rachel Haurwitz | DEF 14A | 2026-04-24 | 0001619856-26-000022 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 21 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 22 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 23 | Section 09b board cost (computed) | Computed | — | computed | Cash 418,148 + equity 0 + all other 0 = 418,148, summed across the director compensation table rows.machine: formula: Σ = 418,148 |
| 24 | Caribou Biosciences, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-24 | 0001619856-26-000022 | CEO total compensation as printed in Caribou Biosciences, Inc.'s own proxy. As printed: 1,840,965. Filing ↗machine: r2 · c39 · span 189876–189885 |